Effect of a new bifunctional nitrosoureido derivative on human colorectal tumor xenografts.
The tumor inhibiting effect of a newly developed bifunctional nitrosoureido derivative (GYKI-13324) was studied on human colorectal tumor xenograft lines. Given orally in single or multiple daily doses, GYKI-13324 produced long-term or total regression of adenomatous, but only marginal growth delay of mucinous tumors. GYKI-13324, with slightly lower toxicity than that of BCNU, seems to be a candidate in the clinical management of colorectal tumors.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002330:Carmustine / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy*; D006801:Humans; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D009607:Nitrosourea Compounds / Q000494:pharmacology*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D014183:Transplantation, Heterologous
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C027990:GYKI 13324; D002330:Carmustine